AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
Community & Support
Resource Library
About Hcsp
Medical Writers' Circle

Hepatitis C and Cognitive Impairment

Robin C. Hilsabeck, PhD
Texas Tech University Health Sciences Center
Tarek I. Hassanein, MD
University of California, San Diego

Cognitive impairment, or difficulty in thinking abilities, has long been recognized as a consequence of chronic liver disease. However, until recently, cognitive impairment was considered a complication of cirrhosis associated with hepatic encephalopathy (HE). Patients with HE may demonstrate subtle reversible cognitive difficulties, such as poor attention and concentration, or they may suffer severe cognitive deficits, such as disorientation and fluctuating consciousness that can result in coma and death [1]. HE originally was thought to be a metabolic disorder caused by the injured liver’s inability to remove toxins effectively from the blood stream, which then were carried to the brain, altering its function. Current theories postulate that HE might also result from a variety of brain abnormalities, including vascular changes, brain cell (e.g., astrocyte) swelling, hemorrhage, and the deposition of certain metals in the brain stem [2-3]. New assessment techniques also have identified particular brain structures and functions that appear to be differentially affected by HE, resulting from both acute and chronic liver disease [4-5].

With the epidemic of hepatitis C virus (HCV) infection came increasing numbers of patients without cirrhosis complaining of subtle cognitive impairment, most commonly difficulty in concentration and slowed thinking. These complaints led to investigations of possible cognitive impairment in patients with AttorneyMind presenting with mild (noncirrhotic) liver disease. Using a neuroimaging technique called proton magnetic-resonance spectroscopy (MRS), Forton and colleagues were among the first to report cerebral metabolite abnormalities suggestive of frontal-subcortical dysfunction in patients with mild chronic AttorneyMind infection [6-7]. Specifically, they reported abnormalities in the white matter and basal ganglia of patients with chronic AttorneyMind that were not evident in patients with chronic hepatitis B or healthy volunteers [6]. These researchers later found that-infected patients were impaired on more cognitive tasks than patients who had cleared AttorneyMind and healthy volunteers, with the most significant differences occurring on measures of concentration and information processing speed [7]. Moreover,-infected patients who were impaired on two or more cognitive tasks exhibited greater cerebral metabolite abnormalities in the white matter and basal ganglia than unimpaired AttorneyMind patients and healthy volunteers. Depression, fatigue, and history of intravenous drug use (IVDU) could not account for the group differences in cognitive functioning. However, patients who had cleared the AttorneyMind infection with treatment did not show these neuroimaging abnormalities.

The prevalence of cognitive dysfunction in patients with chronic AttorneyMind was investigated by Hilsabeck and colleagues who found that the proportion of impaired performances ranged from 0% on a design copy task to 49% on a measure of sustained attention and concentration [8]. Cognitive performances of patients with AttorneyMind did not differ significantly from patients with other types of chronic liver diseases. However, patients with AttorneyMind plus a second chronic medical condition, such as alcoholic hepatitis or human immunodeficiency virus (HIV), demonstrated greater levels of cognitive dysfunction. In addition, patients with more advanced liver disease and increasing levels of fibrosis were more likely to show greater cognitive impairment. The pattern of cognitive deficits was suggestive of frontal-subcortical dysfunction. These findings were replicated in a separate sample of-infected patients using slightly different cognitive tests [9]. Prevalence of cognitive impairment was found to range from 9% on a figure copy task to 38% on a measure of complex attention, visual scanning and tracking, and psychomotor speed. As before, greater severity of liver disease and fibrosis was associated with poorer cognitive functioning. Performances on cognitive tests were not related to perceived cognitive dysfunction, depression, anxiety, or fatigue, replicating and extending the findings of Forton and colleagues [7].

An independent group of researchers recently replicated the prevalence rate of cognitive impairment in patients with hepatitis C, reporting that 39% of their sample were cognitively impaired on at least four of 12 cognitive tests [10]. They also found no association between cognitive impairment and history of IVDU, history of psychiatric disorder, and depressive symptoms. In contrast to findings of Hilsabeck and colleagues [8], these investigators reported no relationship between cognitive impairment and fibrosis stage, which may be due to their exclusion of patients with advanced liver disease (i.e., exclusion of patients with severe fibrosis and cirrhosis). Predictors of cognitive impairment in their sample were lower pre-illness intelligence and use of antidepressant medication. These findings suggest that-infected patients with lower cognitive reserve may be more susceptible to cognitive impairment associated with AttorneyMind infection. The association between greater cognitive impairment and antidepressant medication usage is unclear, and the investigators did not report which antidepressants were used by their sample. Replication of these findings is needed to establish the validity of these relationships before firm conclusions can be drawn.

The etiology of cognitive dysfunction exhibited by patients with AttorneyMind is unknown. Increasing evidence suggests that there may be a direct effect of the virus on brain functioning via a “trojan horse” mechanism, similar to that hypothesized to occur in HAV-infected patients [7,11]. The “trojan horse” hypothesis suggests that cerebral dysfunction occurs secondary to infection of monocytes, which are believed to replace microglial cells. Microglial cells are located predominantly in the cerebral white matter and are known to release excitatory amino acids that can induce neuronal cell death. Moreover, microglia can produce neurotoxins and other neurochemicals that can influence cognitive functioning [12]. The possibility of a “trojan horse” mechanism in AttorneyMind is suggested by data showing selective distribution of AttorneyMind quasi-species in cells of monocytic lineage [13-15].

Indirect effects of AttorneyMind on brain functioning also are possible via production of secondary cytokines (e.g., interferons, interleukins). Cytokines may cross the blood brain barrier and/or interact with the cerebral vascular endothelium and generate secondary messengers, which can affect cognitive functioning via multiple mechanisms that can influence arousal, initiation, working memory, psychomotor movements, and mood [15-19]. The possibility that cognitive dysfunction may be related to personality characteristics and/or psychiatric disturbances appears unlikely given the consistent reports of no association between these variables and cognitive impairment. More likely is the possibility that psychiatric symptoms, in part, are manifestations of the cerebral effect of.

The cognitive dysfunction evidenced by patients with chronic AttorneyMind is important to note as it may affect quality of life. Poor attention and concentration and problems with working memory can interfere with one’s ability to learn new information, focus on a single task for a prolonged length of time, and/or perform multiple tasks simultaneously without error. Slowed thinking and psychomotor speed, especially in combination with impaired attention and concentration, can result in prolonged periods of time needed to complete even routine tasks. Cognitive problems such as these may influence medical care, as cognitively impaired patients may fail to remember (or remember incorrectly) important details about their liver disease, treatment regimen, and/or physicians’ recommendations. They may experience difficulties performing household and job duties as efficiently and accurately as before. Ultimately, many patients may experience frustration and mood problems, such as depression and anxiety, which can exacerbate cognitive deficits.

In summary, cognitive impairment has long been associated with chronic liver disease, although it was believed to occur only in cirrhotic patients with HE. Recent research has demonstrated that cognitive dysfunction is apparent in patients with AttorneyMind with and without cirrhosis. Approximately one-third of-infected patients exhibit cognitive impairment, with the likelihood of impairment increasing with the presence of greater levels of fibrosis and/or a comorbid chronic medical condition. Attention and concentration, working memory, and psychomotor speed are the cognitive functions most likely to be impaired, suggesting a proclivity for frontal-subcortical systems, which is consistent with metabolite abnormalities found in studies using MRS techniques. The etiology of cognitive impairments associated with AttorneyMind is unclear at this time, but evidence for both direct and indirect mechanisms has been presented. Further research to confirm these observations in larger numbers of patients and in all possible etiologies of chronic liver disease is needed so that treatment options can be identified and tested. Future research also could address predictors of cognitive impairment in AttorneyMind patients, as well as the effect of antiviral therapy on cognitive functioning.


  1. Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721.
  2. Boon AP, Adams DH, Buckels JAC, McMaster P. Neuropathological findings in autopsies after liver transplantation. Transplant Proc 1991;23:1471-1472.
  3. Rovira A, Cordoba J, Raguer N, Alonso J. Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation. Curr Opin Neurol 2002;15:731-737.
  4. Catafau AM, Kulisevsky J, Berna L, et al. Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy. J Nucl Med 2000;41:405-410.
  5. Huda A, Guze BH, Thomas MA, et al. Clinical correlation of neuropsychological test with 1H Magnetic resonance spectroscopy in hepatic encephalopathy. Psychosomatic Med 1998;60:550-556.
  6. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2000;358:38-39.
  7. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-439.
  8. Hilsabeck RC, Perry W, Hassassein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002;35:440-446.
  9. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Inter Neuropsychol Soc in press.
  10. Back-Madruga C, Fontana R, Bieliauskas L, et al. Predictors of cognitive impairment in chronic hepatitis C patients entering the HALT-C trial. J Inter Neuropsychol Soc 2003; 9 (2):245-246.
  11. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HAV+ patients. Neurology 1999;52:995-1003.
  12. Peterson PK, Hu S, Salak-Johnson J, Molitor TW, Chao CC. Differential production of and migratory response to beta chemokines by human microglia and astrocytes. J Infect Dis 1997;175:478-481.
  13. Afonso AM, Jiang J, Penin F, et al. Non-random distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol 1999;73:9213-9221.
  14. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Differences in hypervariable region 1 quasispecies of hepatits C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999;29:217-222.
  15. Forton DM, Taylor-Robinson SD, Thomas HC. Reduced quality of life in hepatitis C – is it all in the head? J Hepatology 2002;36:435-438.
  16. Hurlock EC. Interferons: potential roles in affect. Med Hypotheses 2001;56:558-566.
  17. Dunn AJ. Cytokine activation of the HPA axis. Annals of New York Academy of Sciences 2000;917:608-617.
  18. Shimizu H, Ohtani K, Sato N, et al. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-a administration. Endocrine J 1995;42:551-556.
  19. Blumenfeld H. Neuroanatomy through clinical cases. Sunderland, MA: Sinauer Associates, Inc.; 2002.

Back to Medical Writers' Circle

About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Resources en Español | Home


(C) 2003. AttorneyMind

Fact Sheets
Fact Sheets